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Background: There is a growing body of evidence on the risks and benefits of influenza vaccination in 2 
various target groups. Systematic reviews are of particular importance for policy decisions. However, 3 
their methodological quality can vary considerably.  4 
Objectives: To investigate the methodological quality of systematic reviews on influenza vaccination 5 
(efficacy, effectiveness, safety) and to identify influencing factors.  6 
Methods: A systematic literature search on systematic reviews on influenza vaccination was 7 
performed, using MEDLINE, EMBASE and three additional databases (1990-2013). Review 8 
characteristics were extracted and the methodological quality of the reviews was evaluated using the 9 
Assessment of Multiple Systematic Reviews (AMSTAR) tool. U-test, Kruskal-Wallis test, chi-square 10 
test, and multivariable linear regression analysis were used to assess the influence of review 11 
characteristics on AMSTAR-score.    12 
Results: Fourty-six systematic reviews fulfilled the inclusion criteria. Average methodological quality 13 
was high (median AMSTAR-score: 8), but variability was large (AMSTAR range: 0-11). Quality did not 14 
differ significantly according to vaccination target group. Cochrane reviews had higher 15 
methodological quality than non-Cochrane reviews (p=0.001). Detailed analysis showed that this was 16 
due to better study selection and data extraction, inclusion of unpublished studies, and better 17 
reporting of study characteristics (all p<0.05). In the adjusted analysis, no other factor, including 18 
industry sponsorship or journal impact factor had an influence on AMSTAR score.  19 
Conclusions: Systematic reviews on influenza vaccination showed large differences regarding their 20 
methodological quality. Reviews conducted by the Cochrane collaboration were of higher quality 21 
than others. When using systematic reviews to guide the development of vaccination 22 
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When considering the best available evidence regarding vaccination, results of randomized 29 
controlled trials (RCTs), systematic reviews, and meta-analyses on vaccine efficacy and safety are 30 
commonly used to guide immunization policy decisions.  For influenza vaccines, however, the unique 31 
epidemiological features of influenza viruses with seasonal variations potentially leading to a 32 
mismatch between vaccine and circulating strains complicate the interpretation of single studies 33 
reporting data from only one or two seasons and increase the importance of summarized evidence in 34 
terms of systematic reviews. In addition, since most influenza vaccines are licensed only based on 35 
RCTs demonstrating immunogenicity and not efficacy in preventing clinical outcomes, there is a need 36 
to consider high-quality observational studies assessing vaccine effectiveness (1, 2). Finally, the 37 
interpretation of efficacy and effectiveness studies is further complicated by the fact that there are 38 
obvious differences in influenza vaccine efficacy/effectiveness by vaccine type and age-group (3) . 39 
Therefore, systematic reviews of high quality that address the safety and protective effects of 40 
influenza vaccination in various vaccination target groups are of particular importance.  41 
Systematic reviews and meta-analyses are used to synthesize results of primary 42 
investigations on a specific subject and have been advocated as a way to keep up to date with 43 
current medical literature (4). Using a rigorous methodology with a clearly formulated research 44 
question and a comprehensive search strategy, systematic reviews should provide reproducible 45 
results and include all potentially relevant studies, thereby limiting bias and random errors (5, 6). 46 
When quantitative results are statistically summarized in meta-analyses they can provide more 47 
robust estimates than single studies (4, 7). However, systematic reviews and meta-analyses may 48 
differ considerably in their methodological quality (8, 9). Accordingly, systematic reviews with major 49 
methodological flaws might lead to false conclusions on the evidence, which might have a negative 50 
impact on decision-making processes (10). 51 
Therefore, critical appraisal of the quality of systematic reviews is important. Several instruments 52 
have been developed that assess the quality of systematic reviews and meta-analyses (11-13). Based 53 
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on the most commonly used instruments, Shea et al. developed a tool for the assessment of multiple 54 
systematic reviews (AMSTAR) to measure their methodological quality, comprising 11 domains (14). 55 
AMSTAR can be used as a cumulative score where a higher number of fulfilled domains (“yes”) 56 
corresponds to a higher methodological quality, which translates in a maximum (i.e. highest quality) 57 
score of 11 points (15, 16). 58 
The goal of this study was to systematically identify all systematic reviews on the efficacy, 59 
effectiveness and safety of vaccines used against seasonal influenza in various target groups and to 60 
assess their methodological quality using the AMSTAR tool. Furthermore, we investigated which 61 
characteristics had an impact on the quality of these reviews.   62 
 63 
Methods 64 
Literature search and study selection. To identify systematic reviews on influenza vaccination we 65 
performed a systematic literature search (date of search: 15 May 2013) using MEDLINE, EMBASE, 66 
Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effects and Health 67 
Technology Assessment Database (for search strategy, see Appendix 1).   68 
To be eligible, a systematic review had to fulfill the following inclusion criteria: 1) systematic 69 
review on the efficacy, effectiveness and/or safety of vaccines against seasonal influenza; 2) 70 
published after 1990; 3) written in English or German. Two reviewers (CR and TH) independently 71 
screened titles and abstracts of identified publications. Potentially eligible publications were 72 
reviewed as full text. Disagreements were resolved by discussions until consensus was achieved.  73 
 74 
Data extraction and assessement of methodological quality. From each eligible systematic review, 75 
two independent reviewers (CR and TH) extracted study characteristics and assessed methodological 76 
quality. In case of disagreements, a final decision was made by consensus.  77 
The AMSTAR tool was used to determine the methodological quality of the included 78 
systematic reviews (14). Investigators assessed each included review along the 11 domains of 79 
6 
 
AMSTAR (Box). Each domain was answered with either “yes”, “no”, “not applicable (n/a)” or “can’t 80 
answer”. AMSTAR summary score was formed by summarizing the number of domains which were 81 
answered with “yes”. A data base was constructed including the extracted review characteristics and 82 
the results of the quality assessment process for the AMSTAR summary score as well as for all 11 83 
AMSTAR domains.  84 
 85 
Definitions. Vaccination target groups:  Each review was allocated independently by both reviewers 86 
(CR and TH) to one of the following groups according to the vaccination target groups defined in the 87 
respective review by in- and exclusion criteria: healthy children, healthy adults, elderly persons, 88 
health care personell, patients with lung diseases, patienties with malignancies,  89 
immunocompromised patients. Reviews covering healthy adults and healthy children without 90 
exclusion of special risk groups were defined as “general population”. Reviews focusing on specific 91 
vaccines (e.g. only intradermal vaccines) or covering other (e.g. multiple sclerosis) or more than one 92 
of the above mentioned subgroups (e.g. healthy and chronically ill children and adults) were defined 93 
as miscellaneous. Again, any disagreement was resolved by discussion between the authors. 94 
Specialized journal: A journal was defined as  “specialized” if its aims and scopes focuses on  95 
vaccination or infectious diseases.  96 
Impact factor: For the purpose of this study, the Thomson Reuters Impact factor was used as of May 97 
2013 (http://wokinfo.com/essays/impact-factor/). 98 
Journal article version of a Cochrane review: Systematic review that has been published –in addition 99 
to the Cochrane journal-  as a shortened version in a non-Cochrane journal. In addition to the main 100 
analysis which included both versions of these reviews, a sensitivity analysis was performed by 101 
excluding the full Cochrane versions of the respective systematic reviews. 102 
Publication bias: According to the recommended use of the AMSTAR-tool, systematic reviews with 103 
less than 10 studies were scored for domain 10 “yes” if the authors mentioned that publication bias 104 




Statistical analysis. Results of descriptive statistics were displayed as median and range or n (%), as 107 
appropriate. Differences in AMSTAR summary scores according to review characteristics were 108 
compared using Mann-Whitney U-test or Kruskal-Wallis test. Chi-squared test was used to compare 109 
single AMSTAR domains. Multivariable linear regression was applied to analyze the influence of 110 
review characteristics on AMSTAR summary score. Two-sided hypothesis tests were performed and a 111 
p-value of less than 0.05 was considered as statistically significant. All calculation were made using 112 
IBM SPSS Statistics 20.  113 




The systematic literature review led to the identification of 564 publications. After exclusion of 116 
irrelevant records or studies which did not fulfill the inclusion criteria (see Appendix 2 for the list of 117 
excluded studies), a total of 46 systematic reviews (17-62) were found to be eligible (Figure 1). 118 
Review topics covered by the included systematic reviews are shown in Table 1. Two updates of 119 
systematic reviews were published after the time of the literature search and were not included in 120 
this article (63, 64). 121 
Table 2 summarizes major characteristics of the included systematic reviews. About 50% 122 
were published in 2010 or later in a specialized journal. A quarter of them were Cochrane reviews,  123 
less than 20% of the reviews were funded by pharmaceutical companies and about 50% included 124 
observational studies. Observational studies were less likely to be included in Cochrane than in non-125 
Cochrane reviews (3/11 (27.3%) vs. 22/35 (62.9%)) and in reviews funded by pharmaceutical industry 126 
(1/6 (16.7%) vs. 24/40 (60.0%)), respectively; however, these differences were not statistically 127 
significant (p=0.08 for both). 128 
On average, methodological quality of the systematic reviews was high, indicated by a 129 
median AMSTAR summary score of 8, but variability was large (range: 0-11). 130 
We then analyzed whether methodological quality of reviews differed according to review 131 
topic (i.e. vaccination target group). As shown in Figure 2, AMSTAR summary scores did not differ 132 
largely between review topics, except for reviews on vaccination in the general population, which 133 
tended to be of lower quality than those on other topics. However, differences in AMSTAR scores 134 
between topics were not statistically significant. Therefore, we decided to perform all subsequent 135 
analyses on the entire set of reviews as one single study base. 136 
In the next step, we analyzed which characteristics of the reviews had an impact on 137 
methodological quality. Table 3 shows AMSTAR summary scores according to the presence or 138 
absence of major study characteristics (bivariate analyses). Cochrane reviews had a significantly 139 
higher methodological quality than non-Cochrane reviews (p=0.001). Furthermore, reviews published 140 
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in specialized journals were of slightly but significantly lower quality than those which came from 141 
generalized journals (p=0.03). None of the other factors had an impact on methodological quality.  142 
In order to analyze the impact of shortened “journal article versions” of Cochrane reviews, 143 
we performed a sensitivity analysis excluding the full-length Cochrane versions  of the respective 144 
reviews from the database, i.e. references (23, 31, 38, 39) and repeated the main analysis. In this 145 
restricted data set, Cochrane reviews still had significantly higher AMSTAR summary scores (median: 146 
9; range: 8-10) than non-Cochrane reviews (median: 7; range: 0-10; p=0.004), whereas the score did 147 
not differ regarding all other review characteristics (publication date; specialized journal; impact 148 
factor; no. of included studies; inclusion of observational studies; funding). 149 
To further determine the extent by which these factors influenced the methodological quality of the 150 
systematic reviews on influenza vaccination, we performed multivariable linear regression analysis 151 
(Table 4). According to R², 27% of the variability of the methodological quality of the systematic 152 
reviews was explained by the seven factors in the model. However, in this model, only Cochrane 153 
review status (yes/no) had a significant influence on AMSTAR summary score. This result was 154 
confirmed when stepwise regression was performed to eliminate non-significant covariates: Again, 155 
Cochrane review status was the only covariate which influenced AMSTAR summary score (p=0.001; 156 
R²=0.21). Therefore, we aimed to analyze whether these differences in review quality are caused by 157 
particular methodological features of Cochrane reviews. Accordingly, we compared the proportion of 158 
reviews which fulfilled the different AMSTAR domains (i.e., domains were answered by “yes”) 159 
between Cochrane and non-Cochrane reviews (Figure 3). Cochrane reviews had significantly higher 160 
methodological quality (i.e., domains were more often answered by “yes”) regarding domains No. 2 161 
(duplicate study selection and data extraction), No. 4 (status of publication used as inclusion 162 





Discussion  166 
In view of an expanding body of evidence related to the safety and protective effects of influenza 167 
vaccination and the complexity of the topic, we aimed to investigate the methodological quality of 168 
the available systematic reviews. To the best of our knowledge, this is the first study which used the 169 
AMSTAR tool to assess the quality of systematic reviews in the field of immunization in general and 170 
on influenza vaccination in particular. We found that on average systematic reviews on influenza 171 
vaccination had a high quality, with reviews conducted by the Cochrane collaboration being of higher 172 
quality than others. Although AMSTAR score was highest for reviews focusing on influenza vaccines 173 
in healthcare workers, lung diseases and malignancies with a median score of 9, and lowest in 174 
reviews dealing with the general population (median of 5), this difference was not statistically 175 
significant. The fact, that the overall quality of published systematic reviews on influenza vaccination 176 
is generally high is important for clinicians and health policy decision makers when the best available 177 
evidence is considered to guide immunization policy decisions. However, since some reviews 178 
revealed obvious flaws leading to low AMSTAR scores and one review even received an AMSTAR 179 
score of zero, critical appraisal of the methodological quality remains important in the field of 180 
systematic reviews on influenza vaccination. 181 
So far, only one study has assessed the methodological quality of systematic reviews and 182 
meta-analyses on vaccines. Using the Oxman-Guyatt tool, Vito et al. systematically investigated the 183 
methodological quality of systematic reviews of vaccines in general and found it to be not 184 
satisfactory (65). In their paper, they identified major flaws in comprehensiveness of literature 185 
search, selection of studies for inclusion, quality assessment of included studies, and analysis of 186 
publication bias. Methodological quality of the systematic reviews was found to depend on type of 187 
included studies (RCTs vs. observational studies), year of publication, financial support (non-profit vs. 188 
for-profit support), and assessment of statistical heterogeneity. By contrast, in our study only 189 
Cochrane review status (Cochrane review vs. non-Cochrane review) had an impact on the 190 
methodological quality of reviews focusing on influenza vaccines. Differences in the quality between 191 
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Cochrane and non-Cochrane reviews were attributed to duplicate study selection, the inclusion of 192 
grey literature, and the provision of a list of excluded and included studies. However, when 193 
comparing our results with those by Vito et al. it has to be taken into account, that (i) the study of 194 
Vito and colleagues investigated the quality of reviews on all types of vaccinations (although 25 195 
reviews on influenza vaccines were included) and (ii) the methodological quality was assessed by a 196 
different tool (66) and not the AMSTAR instrument, limiting direct comparison. 197 
In line with our results, in other areas of medicine a higher methodological quality of 198 
Cochrane reviews was found when compared with non-Cochrane reviews. In the field of assisted 199 
reproductive technologies Windsor et al. observed that the methodological quality of Cochrane 200 
reviews was superior to non-Cochrane reviews using the AMSTAR tool (15). They identified main 201 
differences regarding the AMSTAR domains No. 1 (‘a priori design’), Nr. 3 (‘comprehensiveness of 202 
literature search’), Nr. 5 (‘list of included and excluded studies’) and Nr. 7 (‘assessment of the 203 
scientific quality of included studies’). Using the ‘Overview Quality Assessment Questionnaire’ 204 
(OQAQ) quality assessment tool, Moseley et al. showed that conduct of systematic reviews on 205 
physiotherapy interventions according to the methodology of the Cochrane Collaboration improves 206 
review quality (67). Finally, applying the Oxman-Guyatt tool Collier et al. found that systematic 207 
reviews of the Cochrane Skin group were methodologically more rigorous than other systematic 208 
reviews in dermatology (68).  209 
Interestingly, in our study we were unable to identify differences in methodological quality 210 
when comparing systematic reviews that were funded by pharmaceutical companies to those 211 
without such funding. In contrast, Jørgensen et al. found that industry supported reviews had more 212 
favorable conclusions and were less likely to report methodological limitations of included trials than 213 
corresponding Cochrane reviews of the same drugs (69). It is important to understand in this respect 214 
that issues like drawing conclusions or highlighting limitations are not captured by tools like AMSTAR, 215 
which are used to measure only the methodological quality of systematic reviews. Therefore, even if 216 
pharmaceutical funding did not affect the methodological quality of influenza vaccination reviews, 217 
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reporting of potential conflicts of interest and funding sources remains important when the results of 218 
systematic reviews are interpreted and conclusions are drawn. 219 
It is furthermore important to note that according to our study, none of the included non-220 
Cochrane reviews and less than 20% of Cochrane reviews declared conflict of interest of all included 221 
studies (AMSTAR domain 11). This is corroborated by Roseman et al. who investigated to which 222 
extend systematic reviews of drug treatments published in the Cochrane Database of Systematic 223 
Reviews reported conflicts of interest from included trials and the review itself. Only 30% of reviews 224 
reported information on funding source of included trials and only 20% reported information on trial 225 
funding for all included trials (70). To this end, there is a need for improvement in both, Cochrane 226 
and non-Cochrane reviews in reporting potential conflicts of interest for all included studies and the 227 
review itself. 228 
According to  AMSTAR domain 10, publication bias was reported in only 36.4% of Cochrane 229 
and 40% of non-Cochrane reviews. Publication bias can occur when studies on the same research 230 
question are more likely to be published when containing statistically significant or “hoped-for” 231 
results (71). Since undetected publication bias may lead to imprecise or misleading results of 232 
systematic reviews, statistical approaches such as funnel plots and regression test proposed by Egger 233 
and colleagues has been developed and should be used to detect publication bias (72). However, 234 
even if  measures to identify publication bias have improved in recent years (73), the reporting rate 235 
in reviews on influenza vaccines is still not satisfactory. It should be emphasised, that the purpose of 236 
this paper was not to analyze or discuss results of included reviews and that even reviews of high 237 
methodological quality should be interpreted with caution. For example, even “empty reviews” that 238 
did not identify any study to be eligible can reach a high AMSTAR-score if performed thoroughly. And 239 
for certain research questions a review based solely on RCTs might provide only limited evidence, 240 
irrespective of its methodological quality. In such cases, inclusion of observational studies might 241 
increase the overall value of the review, but this does not necessarly translate to a higher 242 
methodological quality as indicated by a higher AMSTAR score. Thereby, AMSTAR score, as a 243 
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measure of methodological quality, does not provide information on the usefulness of the results of 244 
the respective systematic review for the development of prevention policies. 245 
It is possible, that differences in the average AMSTAR-scores may be partly explained by the 246 
fact, that Cochrane authors could publish their articles in an online journal with unlimited space, 247 
whereas non-Cochrane authors publish in other journals with limitation of word numbers. However, 248 
the sensitivity analysis revealed, that the impact of unlimited space of Cochrane journals was small in 249 
regard of the methodological quality. Moreover, since most AMSTAR-items (except item 5) could be 250 
answered by a single sentence and almost all journals offer the opportunity to upload online 251 
supplementary material as standard practice, these issues can be easily met also by authors of 252 
standard journal articles. In general, methodological flaws in the conduct of systematic reviews could 253 
be avoided by consulting references such as the Cochrane handbook before starting a systematic 254 
review. 255 
Our study has several strengths: It is based on a a systematic literature search strategy, 256 
thereby ensuring comprehensiveness. Furthermore, the AMSTAR tool was applied to systematic 257 
reviews on vaccination which covered a variety of vaccination target groups. However, our approach 258 
was limited to English and German language papers and to those published after 1990, which were 259 
chosen for the reason of practicability. 260 
In summary, this methodological study shows that systematic reviews on influenza 261 
vaccination had on average a high methodological quality but variability was large. Reviews 262 
conducted by the Cochrane collaboration were of higher quality than others, whereas other factors 263 
such as industry sponsorship, journal impact factor, and type of included studies did not significantly 264 
influence the methodological quality of systematic reviews on this topic. Our findings support the 265 
notion that a high methodological quality is the basic precondition of systematic reviews for 266 
identifying the best available evidence regarding specific research questions. However, a high 267 
methodological quality does not automatically reflect usefulness of the content of a review. To this 268 
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end, both methodological quality of a review and its content have to be considered when using 269 
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Table 1: Topics of included systematic reviews on influenza vaccination  
Topic (vaccination target groups ) N (reviews) 
General population 3 
Healthy children 8 
Healthy adults 3 
Elderly persons 4 
Health care workers1 5 
Patients with lung diseases2 5 
Immunocompromized patients3 4 
Patients with malignancies 2 
Miscellaneous 12 
1 also includes studies on indirect benefits for other groups, e.g. patients managed by health care 
personnel 
2 incl. studies on patients with COPD, asthma, cystic fibrosis and bronchiectasis 





Table 2: Characteristics of included systematic reviews 
Characteristics of reviews (n=46) Median (range) or n (%) 
Year of publication  2010 (1995-2013) 
Specialised journal 26 (57) 
Impact factor 3.5 (0-39) 
Cochrane review 11 (24) 
No. of pages 11.5 (5-227) 
   - without Cochrane reviews 10 (5-74) 
No. of included studies 13 (0-209) 
Observational studies included 25 (54) 
Funding by pharmaceutical company 6 (13) 





Table 3: AMSTAR summary scores according to characteristics of systematic reviews  
Characteristics of reviews Yes1  No1 p-value2 
Publication after 20073 8 (2-11) 7 (0-10) 0.29 
Specialised journal 7 (0-10) 8 (5-11) 0.03 
Impact factor > 3.54 8 (4-11) 7 (0-10) 0.20 
Cochrane review 9 (8-11) 7 (0-10) 0.001 
No. of included studies > 134 7 (3-11) 8 (0-10) 0.25 
Observational studies included 8 (0-11) 8 (2-10) 0.55 
Funding by pharmaceutical company 6 (2-9) 8 (0-11) 0.38 
1 Median (range) 
2 Mann-Whitney U-Test 
3 AMSTAR was published first in 2007   




Table 4: Multivariable linear regression analysis: AMSTAR summary score according to characteristics 
of systematic reviews (R²=0.27) 
Characteristics in the model Beta T p-value 
Publication year after 20071 -0.006 -0.03 0.97 
Specialised journal -0.055 -0.28 0.78 
Impact factor > 3.52 -0.19 -1.03 0.31 
Cochrane review  0.58 2.40 0.02 
No of included studies > 132 0.08 0.53 0.60 
Observational studies included  0.11 0.69 0.50 
Funding by pharmaceutical company  -0.17 -1.07 0.29 
1 AMSTAR was published first in 2007   




Box: Description of AMSTAR domains (according to (14)) 
1.  Was an ‘a priori’ design provided? 
2.  Was there duplicate study selection and data extraction? 
3. Was a comprehensive literature search performed? 
4. Was the status of publication (i.e., grey literature) used as an inclusion criterion? 
5. Was a list of studies (included and excluded) provided? 
6. Were the characteristics of the included studies provided? 
7. Was the scientific quality of the included studies assessed and documented? 
8. Was the scientific quality of the included studies used appropriately in formulating 
 conclusion?  
9. Were the methods used to combine the findings of the studies appropriate? 
10. Was the likelihood of publication bias assessed? 




Figure 1: Selection process for systematic review of systematic reviews on influenza vaccination.  
 
Figure 2: AMSTAR scores according to vaccination target groups of systematic reviews. Data are 
medians and ranges. AMSTAR scores do not differ significantly between target groups (p=0.08; 
Kruskal-Wallis test). HCW: health care workers.   
 
Figure 3: Individual AMSTAR scores for each domain (1-11) given as percentage of reviews receiving a 
“Yes” in Cochrane reviews (n=11) vs. non-Cochrane reviews (n=35). Groups are significantly different 
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Figure 1: Selection process for systematic review of systematic reviews on influenza 






Figure 2: AMSTAR scores according to topics of systematic reviews. Data are medians and 
ranges. AMSTAR scores do not differ significantly between topics (p=0.08; Kruskal-Wallis 














Figure 3: Proportion of reported AMSTAR domains (items 1-11) in Cochrane vs. Non-
Cochrane reviews. Groups are significantly different for items 2, 4 and 5 (p<0.05; chi-squared 
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